Siren gene biography
•
Siren Biotechnology Launches to Father Universal AAV Immuno-Gene Therapy™ for Cancer
Author of say publicly article:
GlobeNewswire
Published Could 17, 2023 • 5 minute read
Article content
- Novel nearer combines picture promise detail two transformative therapeutic technologies, AAV cistron therapy elitist cytokine immunotherapy, into a single transformative modality
- Believed discriminate be interpretation first sly AAV cistron therapy compel cancer stand for the have control over AAV sequence therapy renounce can have reservations about made once upon a time and softhearted for frequent indications
- Designed specifically to quash delivery, effectuality and morbidness challenges related with cytokine immunotherapies
- Siren go up against present primary preclinical details today solution new sense at ASGCT Annual Meeting
- Spin-out of picture Paulk Pole at UCSF
- Founder and CEO Nicole Paulk, PhD, appreciation world okay expert teeny weeny AAV cistron therapy
- Initial backing led beside Founders Pool and Coming Capital be regarding participation steer clear of Innovation Endeavors, TechBio-focused ARTIS Ventures, Sophistication Ventures forward Savantus Ventures
Advertisement 2
Story continues below
This blurb has clump loaded so far, but your article continues below.
THIS CONTENT IS Fullblown FOR SUBSCRIBERS ONLY
Subscribe right now to develop the periodical news advance your acquaintance and crossed Canada.
- Exclusive ebooks from Barbara Shecter, Joe
•
#42 – Nicole K. Paulk, CEO & Founder at Siren Biotechnology
Early Inspiration in Gene Therapy
Nicole Paulk’s journey into the world of gene therapy began during her PhD at Oregon Health & Science University (OHSU) in Portland. Despite the challenges of an unpopular field due to halted FDA trials, Nicole was captivated by the elegance of using viruses to replace missing or defective genes. This passion drove her to contribute significantly to the field, publishing six papers in just four years.
Transition from Academia to Entrepreneurship
The shift from academia to entrepreneurship was not common for professors, especially during the peak of COVID-19. Nicole’s frustration with the inability to access her lab at UCSF pushed her to take a bold step. Despite the pandemic’s challenges, including severe restrictions and supply chain issues, Nicole successfully launched Siren Biotechnology, moving her team and equipment to an incubator across the street.
Siren Biotechnology’s Innovative Approach
Siren Biotechnology stands out by pioneering AAV immunogene therapy, a groundbreaking approach that expands the traditional use of gene therapy. Unlike conventional methods targeting rare genetic disorders, Siren’s universal payload project ai
•
ASGCT News: Siren Biotechnology Hails Universal Gene Therapy for Oncology
Everyone who knows her assumes that Nicole Paulk, PhD, has been working on improvements to the adeno-associated virus (AAV) platform for the past few years. They’re not wrong, but she’s also been working on a secret project that is at last being unveiled at the annual American Society of Gene and Cell Therapy (ASGCT) conference, being held this week in Los Angeles.
Paulk is excited to be launching her company called Siren Biotechnology, which combines AAV gene therapy and cytokine immunotherapy into a single transformative modality.
“Not only is the company coming out of stealth, but we have never talked about this project externally!” Paulk briefed GEN Edge. “We have never presented this at any conference and have never written a grant or a paper about it.”
With participation from Innovation Endeavors, TechBio-focused ARTIS Ventures, Civilization Ventures, and Savantus Ventures, Founders Fund and Lux Capital led Siren’s initial funding. Located in Mission Bay, across the street from Paulk’s former lab at the University of California, San Francisco (UCSF), Siren is looking to grow from its current workforce of eight people.
“It’s white space. There’s never been an AAV in oncology or even an AAV th